

# Hormonal Regulation of Nutrients

## Food intake & Obesity

**PHRM 142**

Physiology & Pathophys. III

November 6, 2013

-----  
**Roshanak Rahimian**, *Pharm.D., Msc., Ph.D.*

*Professor*

Thomas J. Long School of Pharmacy & Health Sciences

University of the Pacific

**Office Hours: T & R: 1:00-2:00 pm, C117**

[rrahimian@pacific.edu](mailto:rrahimian@pacific.edu)

✓ Endocrine pancreas . . .

✓ Pancreatic Hormones . . .

✓ Properties, Secretion & Actions . . .

❖ Hormonal Regulation of Nutrients

— Responses to feeding & post-absorptive state

— Effects of Exercise

❖ Food intake & Obesity

# Regulation of Blood Nutrient Levels





Figure. 18.18,  
Seeley

# Regulation of Blood Glucose Concentration

## Response to Feeding (soon after a meal)



Martini  
Fig. 18-19

# Regulation of Blood Nutrient Levels




Figure 18.18,  
Seeley

# Hormonal changes in post-absorptive state

---

## ❖ Decreased insulin secretion

- Decreases muscle uptake of glucose
- Increases hepatic glycogenolysis & gluconeogenesis
- Increases lipolysis

## ❖ Increased glucagon secretion

- Increases hepatic glycogenolysis & gluconeogenesis

## ❖ Increased cortisol secretion

- Increases **protein catabolism**
- Increases **gluconeogenesis**
- Increases **lipolysis**

## ❖ Increased Growth hormone

- **Antagonizes the action of insulin** on glucose utilization in muscle
- Activates **lipolysis**
- Facilitates **gluconeogenesis**

Table 19-2, G&G

# Short-Term Starvation

---


- ❖ 3 - 7 day fast → continuation of processes begun in post-absorptive state.
  - Gluconeogenesis, lipolysis, ketogenesis all stimulated.
  - Increased protein catabolism.

# Long-Term Starvation

---

- ❖ At > 7 days fasting:
  - Protein catabolism ↓
  - Blood ketone ↑
  - Brain utilization of ketones ↑ (reduces dependence on glucose).

# Regulation of Blood Nutrients During Exercise




Seeley  
Fig. 18.19




# Regulation of Blood Nutrients During Exercise

Seeley  
Fig. 18.19



# Short-term/Heavy Exercise

**REVIEW**



- √ Endocrine pancreas . . .
- √ Pancreatic Hormones . . .
  - √ Properties, Secretion & Actions . . .
- √ Hormonal Regulation of Nutrients
- ❖ Food intake & Obesity . . .

# Obesity

---

❖ The presence of “**abnormal or excess**” amount of body fat leads to higher body weight.

❖ **Body Mass Index (BMI)** = 
$$\frac{\text{Body weight (Kg)}}{\text{Height (m)}^2}$$

— (e.g., Wt: 120 pounds  $\approx$  54 kg & H: 1.60 m)

— BMI:  $54 / 2.56 = 21$                       1 pound = 0.453 kg

# Classification of overweight & obesity based on BMI

	BMI (Kg/m <sup>2</sup> )
Underweight	< 18.5
Normal	18.5-24.9
Overweight	25.0-29.9
Obesity	
Grade I	30.0-34.9
Grade II	35.0-39.9
Grade III	> 40.0

G&G, Table 21-1.

❖ Waist/Hip Ratio (WHR of Healthy women= $<0.8$  and men= $<0.9$ )

## ❖ Diseases Associated with Obesity\*

---

- Hypertension
- Hyperlipidemia & Dyslipidemia
- Atherosclerosis, Coronary Heart Disease, MI & Stroke
- Type 2 Diabetes “Chicken-or-egg” relationships . We view obesity as both cause & consequence of type 2 diabetes!
- Gallbladder Disease
- Osteoarthritis
- Cancer (e.g. endometrial, breast, prostate, and colon cancer)

# Metabolic syndrome

---


- ❖ A group of risk factors that increases the risk of CVD, stroke and other health problems, such as diabetes.
  - A large waistline: central or abdominal obesity (For men: 40 inches or larger; For women: 35 inches or larger)
  - A high triglyceride level (150 mg/dL or higher) or using a lipid lowering agent
  - A low HDL level (< 40 mg/dL in males, < 50 mg/dL in females) or using a lipid lowering agent
  - High blood pressure (systolic BP > 130 or diastolic BP >85 mm Hg) or using a BP lowering agent
  - High fasting plasma glucose level (FPG) (>100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes
- ❖ To be diagnosed with metabolic syndrome, you would have at least three of these risk factors.

# Abdominal obesity!

---

## Is the Apple or Pear-Shaped Body Type More Dangerous?


- ❖ A new research from Cambridge (The Lancet, August 2012) is challenging the medical notions that "apple-shaped" people with more fat around their waist are at higher risk of MI and strokes than "pear-shaped" people with fatter bottoms and hips.





# Obesity: Metabolic Disorder of Energy Balance

---



# ob/ob Mouse Model of Obesity


---

- ❖ The mouse *ob* gene encodes a 167 aa protein named *leptin*.
- ❖ Human leptin shares 84% sequence identity to mouse leptin.
- ❖ A link exist between obesity and leptin resistance.




A comparison of a ob mouse with leptin deficiency (left) and a normal mouse (right)

# Background



# How can leptin control food intake?




# Is there a specific receptor for leptin?

---

- ❖ Located in brain as well as in peripheral tissues:
  - SKM, liver, kidney, pancreas, GI, heart

# Reversal of Insulin Resistance by Leptin

- ❖ Insulin resistance of type II diabetes partly due to high levels of lipids in SKM.
- ❖ SKM is one of the primary glucose-consuming tissues, giving it a central role in insulin resistance.
- ❖ Leptin activates **AMPK**. AMPK phosphorylates and inactivates ACC, acetyl-CoA carboxylase.
- ❖ ACC catalyzes the production of malonyl-CoA from acetyl-CoA.
- ❖ Malonyl-CoA in turn is an inhibitor of the import of fatty acids into MQ by **carnitine palmitoyl-transferase I** for oxidation and energy production .



- ❖ In presence of leptin, AMPK is activated, ACC is inhibited, and malonyl-CoA levels fall, increasing the oxidation of FA and reducing the lipid content of cells. The reduced lipid content in SKM allows insulin signaling & glucose consumption to return to their normal levels, reducing insulin resistance.

Adapted from BioCarta

# Summary: Reversal of Insulin Resistance by Leptin

---

- ❖ Insulin resistance of type II diabetes partly due to high levels of lipids in liver and SKM.
- ❖ Leptin acts directly on liver and SKM cells where it activates AMPK and stimulates FA oxidation in mitochondria. This reduces the storage of fat in those tissues.
- ❖ The reduced fat content in SKM and liver allows insulin signaling & glucose utilization to return to their normal levels, reducing insulin resistance or increasing insulin sensitivity.
- ❖ In liver, reduces gluconeogenesis

# In Obesity:

---

❖ Defect may be present in:

- Leptin
- Leptin transport across bbb
- Leptin receptors (*db/db* mouse model of diabetes)
- Leptin signal transduction
- Human obesity involves leptin resistance in the face of high endogenous leptin rather than leptin deficiency.



# Additional Factors Causing Obesity

---

- ❖ Underlying disease (eg., hypothyroidism)
- ❖ Eating disorders
- ❖ Certain medications (eg., anti-psychotics)
- ❖ Inactive lifestyle
- ❖ Insufficient sleep!
  - Increased Ghrelin (a hunger hormone), decreased leptin (a hormone that tells your stomach that it's full)
- ❖ Chronic stress!
  - increased Ghrelin may predispose people to post-traumatic stress disorder (PTSD)
- ❖ Sudden smoking cessation


# Some Facts Regarding Obesity

---

- ❖ Number of fat cells is likely established during infancy, and obesity during adulthood may result from hypertrophy rather hyperplasia.
- ❖ *Where* fat is deposited is more important than *how much* is deposited. Visceral or central obesity is far more important than subcutaneous or peripheral fat.  
(Atten: New research from Cambridge published in the Lancet, 2012)

# Specific Role of Adipocyte-released Secretagogues

---



❑ Adipocytes, consisting of over one billion cells not only store TG in fat depots to provide energy reserves, but constantly communicates with other tissues by adipocyte-released secretagogues .

❑ Visceral fat depots release inflammatory adipokines, along with FFA, provide the pathophysiologic basis for insulin resistance & type 2 diabetes.

# Anti-inflammatory Secretagogues

---

- ❖ To counter the inflammatory secretagogues (eg., FFA, TNF- $\alpha$ ), adipose cells also secrete anti-inflammatory hormones, such as adiponectin and visfatin.
- ❖ Adiponectin, visfatin and leptin enhance insulin sensitivity.
- ❖ Adiponectin deficiency, inflammatory adipokines and excessive FFA, all contribute to insulin resistance, obesity, hypertension, dyslipidemia, and atherosclerosis.
- ❖ Interestingly, leptin may act as both an anti-inflammatory and pro-inflammatory secretagogue, in that it enhances insulin sensitivity for glucose uptake in muscle but may promote some inflammation and angiogenesis at other sites.

# Treatment of obesity

---

- ❖ Diet & Physical activity

- ❖ Medications

- Appetite suppressant drugs such as amphetamines and *leptin*\*
- Drugs such as NPY inhibitor promotes weight loss (e.g. fluoxetine)

- ❖ Thermogenic agents

- ❖ such as leptin\* and exercise (exercise is most effective prescription for weight loss)

- ❖ Surgical treatment of obesity

# Treatment of obesity

- ❖ Although administration of leptin may be effective in a few who are leptin deficient, most obese individuals are leptin resistant & have high levels of leptin.
- ❖ This explains in part why administration of leptin has not been shown to be effective in suppressing appetite in most obese.
- ❖ But why amphetamines and SSRI?

**TABLE 140–2.** Effects of Various Neurotransmitters, Receptors, and Peptides on Food Intake

Neurotransmitter/ Receptor/Peptide	Action	Food Intake
Norepinephrine	Increase concentration	Decrease
$\alpha_1$	Stimulate receptor	Decrease
$\alpha_2$	Stimulate receptor	Increase
$\beta_2$	Stimulate receptor	Decrease
Serotonin	Increase concentration	Decrease
5-HT <sub>1A</sub>	Stimulate receptor	Increase
5-HT <sub>1B</sub>	Stimulate receptor	Decrease
5-HT <sub>2C</sub>	Stimulate receptor	Decrease
Histamine		
H <sub>1</sub>	Stimulate receptor	Decrease
H <sub>3</sub>	Stimulate receptor	Decrease
Dopamine		
D <sub>1</sub>	Stimulate receptor	Decrease
D <sub>2</sub>	Stimulate receptor	Decrease
Leptin	Increase concentration	Decrease
Neuropeptide Y	Increase concentration	Increase
Galanin	Increase concentration	Increase